PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 31, 2026Heart Rhythm

Adjunctive ablation at the mitral isthmus in patients with left ventricular pacing leads: A retrospective multicenter analysis of safety and feasibility

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Atrial arrhythmias often coexist with LV systolic dysfunction requiring CRT, but the safety and feasibility of VOMEI±CS RFA in patients with CRT needed evaluation.

Is Vein of Marshall Ethanol Infusion (VOMEI) ± coronary sinus ablation (CS RFA) safe and feasible in patients with left ventricular pacing leads?

Population

Consecutive patients with CRT and contemporaneous controls without CRT undergoing VOMEI±CS RFA

Comparison

Patients with CRT vs contemporaneous controls without CRT

Design

Retrospective multicenter comparative study

Follow-up

43±21months

Key result

Vein of Marshall Ethanol Infusion (VOMEI) was highly feasible in patients with CRT compared to controls without CRT (94% vs 97%, P=0.92), with similar complication rates (6% vs 3%, P=0.54).

Authors

APAllan PlantGDGeoffroy DitacPKPhilipp Krisai

Discussion

Loading...

Member takes

Overview

Supports VOMEI feasibility in CRT patients; leaves open efficacy and long-term lead effects in prospective trials.

Key Points

  • To assess the safety, feasibility, and outcomes of Vein of Marshall Ethanol Infusion (VOMEI) ± Coronary Sinus Ablation (CS RFA) in patients undergoing cardiac resynchronization therapy (CRT).
  • Retrospective multicenter analysis of patients who underwent VOMEI ± CS RFA at two centers.
  • Comparison with controls without CRT who also underwent VOMEI ± CS RFA.
  • Recorded clinical characteristics, procedural outcomes, and arrhythmia recurrence within 12 months.
  • VOMEI was feasible in 94% of CRT patients and 97% in controls (P=0.92).
  • Complications occurred in 5% of cases, with no significant morbidity.
  • Arrhythmia recurrence within one year was 42% in CRT patients versus 24% in controls.

Study Design

Type

Cohort

Multicenter

Yes

Structured PICO

Is Vein of Marshall Ethanol Infusion (VOMEI) ± coronary sinus ablation (CS RFA) safe and feasible in patients with left ventricular pacing leads?

P
Population
Patients with left ventricular pacing leads (CRT) undergoing Vein of Marshall Ethanol Infusion (VOMEI) ± coronary sinus ablation (CS RFA), and contemporaneous controls without CRT.
I
Intervention
Vein of Marshall Ethanol Infusion (VOMEI) ± coronary sinus ablation (CS RFA)
C
Comparator
Contemporaneous controls without CRT undergoing VOMEI ± CS RFA
O
Outcome
Safety, feasibility, and outcomes including arrhythmia recurrence within 12 months, lead parameters pre- and post-ablation, and lead dysfunction over 43±21 months follow-upsafety

Main Result

Absolute Event Rate: 94% vs 97%

p-value: p=0.92

Vein of Marshall Ethanol Infusion and coronary sinus ablation are feasible and safe in patients with left ventricular pacing leads, with a low risk of clinically significant lead dysfunction.

Cite This Study

Plant et al. (2026) conducted a cohort in Atrial arrhythmias with cardiac resynchronisation therapy (CRT). VOMEI ± CS RFA in patients with CRT vs. VOMEI ± CS RFA in patients without CRT was evaluated on Feasibility of VOMEI (p=0.92). Vein of Marshall Ethanol Infusion (VOMEI) was highly feasible in patients with CRT compared to controls without CRT (94% vs 97%, P=0.92), with similar complication rates (6% vs 3%, P=0.54).

synapsesocial.com/papers/6a025cb5edf6f481385948e9https://doi.org/10.1016/j.hrthm.2026.02.051
View Full Paper
Ask AI
Bookmark
Share